Methylglyoxal Acts as a Tumor-Promoting Factor in Anaplastic Thyroid Cancer

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Methylglyoxal (MG) is a reactive dicarbonyl compound implicated in advanced glycation end product (AGE) formation.
• While previously considered cytotoxic with anticancer potential, MG is now recognized as protumorigenic in certain cancers.
• Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited effective treatment options, necessitating a deeper understanding of its molecular drivers.

Purpose of the Study:

• To investigate the role of MG and MG-mediated dicarbonyl stress in the aggressiveness of anaplastic thyroid cancer (ATC).
• To compare MG adduct levels in ATC versus papillary thyroid cancer (PTC) to assess MG's potential protumorigenic role.

Main Methods:

• Immunohistochemistry was employed to quantify MG protein adducts in human ATC and PTC tissues.
• In vitro experiments assessed the effects of MG adduct accumulation on ATC cell phenotype, migration, and invasion.
• Aminoguanidine (AG), an MG scavenger, and resveratrol, a Glyoxalase 1 (Glo1) activator, were used to evaluate therapeutic potential.

Main Results:

• Significantly higher levels of MG adducts were observed in ATC compared to PTC.
• In vitro, MG adduct accumulation in ATC cells correlated with a mesenchymal phenotype and enhanced migration/invasion.
• Treatment with AG or resveratrol reversed the protumorigenic effects of MG, reducing invasiveness.

Conclusions:

• This study provides the first evidence that MG, through AGE formation, acts as a tumor-promoting factor in anaplastic thyroid cancer.
• The findings suggest that targeting MG accumulation via scavengers or enhancing its metabolism through Glo1 activators could be promising therapeutic strategies for ATC.